Related Experiment Videos
Non-A, non-B hepatitis: evolving epidemiologic and clinical perspective.
Seminars in Liver Disease
|February 1, 1986
Summary
Non-A, Non-B hepatitis (NANB hepatitis) is a significant health concern, often transmitted through transfusions and leading to chronic liver disease. Identifying specific NANB hepatitis agents and developing effective therapies are crucial for public health.
Area of Science:
- Hepatology
- Virology
- Transfusion Medicine
Background:
- Non-A, Non-B hepatitis (NANB hepatitis) agents are implicated in a significant proportion of transfusion-associated hepatitis (TAH) and sporadic hepatitis cases.
- NANB hepatitis exhibits diverse transmission routes, including transfusion, percutaneous inoculation, and enteric transmission, with distinct epidemiological patterns.
Purpose of the Study:
- To review the evidence for NANB hepatitis agents beyond HAV and HBV.
- To delineate the clinical features, transmission patterns, and long-term sequelae of NANB hepatitis.
- To highlight the challenges in diagnosis and the urgent need for specific serologic markers and effective therapies.
Main Methods:
- Review of existing epidemiological, clinical, and pathological data on NANB hepatitis.
- Serologic exclusion to identify cases attributable to NANB hepatitis agents.
- Histological examination of liver biopsies to assess chronic liver disease.
Main Results:
- NANB hepatitis accounts for over 90% of TAH and a substantial percentage of sporadic hepatitis.
- Percutaneously transmitted NANB hepatitis frequently leads to chronic hepatitis and cirrhosis, with a higher incidence than non-percutaneous forms.
- An asymptomatic chronic NANB hepatitis carrier state appears more prevalent than chronic HBV carriers; specific causal agents remain unidentified.
Conclusions:
- Evidence strongly suggests the existence of multiple NANB hepatitis agents, including blood-borne and enterically transmitted forms.
- Effective therapy and immunoprophylaxis for NANB hepatitis are currently lacking.
- Development of virus-specific serologic markers and interim screening strategies are essential to reduce NANB hepatitis transmission, particularly post-transfusion.